III. Efficacy

  1. Very effective in combination with Zidovudine (AZT)

IV. Adverse Effects

  1. See nRTI for adverse effects attributed to the class
  2. Generally Well tolerated
  3. Similar adverse effects to Zidovudine (AZT) but much less severe
    1. Gastrointestinal upset
    2. Neutropenia
  4. Hepatitis B infection flares on Medication Withdrawal

V. Dosing

  1. Adults: 150 mg twice daily or 300 mg orally daily

Images: Related links to external sites (from Bing)

Related Studies (from Trip Database) Open in New Window

Cost: Medications

lamivudine (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing)
LAMIVUDINE 10 MG/ML ORAL SOLN Generic $0.33 per ml
LAMIVUDINE 100 MG TABLET Generic $5.31 each
LAMIVUDINE 150 MG TABLET Generic $1.53 each
LAMIVUDINE 300 MG TABLET Generic $3.77 each
LAMIVUDINE HBV 100 MG TABLET Generic $5.31 each
LAMIVUDINE-ZIDOVUDINE TABLET Generic $1.82 each

Ontology: Lamivudine (C0209738)

Definition (NCI) A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP). In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA. In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. (NCI04)
Definition (NCI_NCI-GLOSS) A drug used to treat infection caused by viruses.
Definition (CSP) zalcitabine analog
Definition (MSH) A reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease.
Definition (PDQ) A synthetic nucleoside analogue with activity against hepatitis B virus (HBV) and HIV. Intracellularly, lamivudine is phosphorylated to its active metabolites, lamiduvine triphosphate (L-TP) and lamiduvine monophosphate (L-MP). In HIV, L-TP inhibits HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleoside analogue into viral DNA. In HBV, incorporation of L-MP into viral DNA by HBV polymerase results in DNA chain termination. L-TP is a weak inhibitor of mammalian DNA polymerases alpha and beta, and mitochondrial DNA polymerase. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42593&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42593&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1471" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Nucleic Acid, Nucleoside, or Nucleotide (T114)
MSH D019259
SnomedCT 108698001, 386897000
LNC LP21312-1, MTHU013847
English 3TC, 2',3' Dideoxy 3' thiacytidine, 2',3'-Dideoxy-3'-thiacytidine, 2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)-, Lamivudine, THREE TC, DIDEOXYTHIACYTIDINE 002 003 003, 2'3' dideoxy 3' thiacytidine, lamivudine (medication), LAMIVUDINE, Lamivudine [Chemical/Ingredient], 3tc, lamiVUDine, LamiVUDine, 3'-Thia-2',3'-dideoxycytidine, 4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone, lamivudine, Lamivudine (product), Lamivudine (substance)
Swedish Lamivudin
Czech lamivudin
Finnish Lamivudiini
Russian 2',3'-DIDEZOKSI-3'-TIATSITIDIN, LAMIVUDIN, 2',3'-ДИДЕЗОКСИ-3'-ТИАЦИТИДИН, 3TC, ЛАМИВУДИН
German DREI TC, DIDESOXYTHIACYTIDIN 002 003 003, 3TC, 2'3'-Didesoxy-3'-thiacytidin, Lamivudin
Polish Lamiwudyna
Japanese 2',3'-ジデオキシ-3'-チアシチジン, ラミブジン
Spanish lamivudina (producto), lamivudina (sustancia), lamivudina, 3TC, 2',3'-Didesoxi-3'-tiacitidina, Lamivudine
French 3TC, Didésoxy-2',3' thiacytidine-3', Lamivudine
Italian Lamivudina
Portuguese 3TC, 2',3'-Didesoxi-3'-tiacitidina, Lamivudina